The Dawning of a New Day in CKD Anemia Care?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2021
   Trial
2. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial.American journal of nephrology · 2021
   Trial
3. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.American journal of nephrology · 2017
   Trial
4. Efficacy of daprodustat on anemia in hemodialysis patients with sustained inflammation: a case report.CEN case reports · 2022
   Article
5. Efficacy of Different Doses of Daprodustat for Anemic Non-dialysis Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.Journal of clinical medicine · 2022
   Review
6. Biomarkers of iron metabolism in chronic kidney disease.International urology and nephrology · 2021
   Review
7. Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2020
   Article
8. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease.Clinical kidney journal · 2019
   Article
9. Remote ischaemic preconditioning: closer to the mechanism?F1000Research · 2016
   Review

Corrections and comments

• Comment on
  Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.2016
• Comment on
  Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as